Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.24 Insider Own52.82% Shs Outstand58.22M Perf Week-3.83%
Market Cap131.08M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float27.36M Perf Month-8.13%
Income-126.33M PEG- EPS next Q-0.13 Inst Own37.53% Short Float / Ratio4.49% / 10.03 Perf Quarter0.44%
Sales0.00M P/S- EPS this Y11.14% Inst Trans-1.20% Short Interest1.23M Perf Half Y-23.91%
Book/sh3.52 P/B0.64 EPS next Y59.02% ROA-42.04% Target Price2.00 Perf Year-35.98%
Cash/sh4.03 P/C0.56 EPS next 5Y25.90% ROE-48.55% 52W Range1.59 - 3.64 Perf YTD-31.93%
Dividend- P/FCF- EPS past 5Y- ROI-49.80% 52W High-37.91% Beta-0.07
Dividend %- Quick Ratio19.05 Sales past 5Y0.00% Gross Margin- 52W Low42.14% ATR0.10
Employees120 Current Ratio19.05 Sales Q/Q- Oper. Margin0.00% RSI (14)42.85 Volatility3.74% 4.87%
OptionableYes Debt/Eq0.26 EPS Q/Q12.17% Profit Margin- Rel Volume0.94 Prev Close2.27
ShortableYes LT Debt/Eq0.24 Earnings- Payout- Avg Volume122.34K Price2.26
Recom3.50 SMA20-2.83% SMA50-4.98% SMA200-11.99% Volume115,587 Change-0.44%
Date Action Analyst Rating Change Price Target Change
Feb-23-23Downgrade Cowen Outperform → Market Perform
Feb-23-23Downgrade Cantor Fitzgerald Overweight → Neutral $3
Feb-23-23Downgrade BofA Securities Neutral → Underperform $3 → $2
Jan-25-23Downgrade BTIG Research Buy → Neutral
Jan-18-23Downgrade BofA Securities Buy → Neutral $7 → $3
Jan-06-23Downgrade SVB Leerink Outperform → Mkt Perform $11 → $2
Jan-06-23Downgrade BMO Capital Markets Outperform → Market Perform $14 → $7
Sep-15-22Initiated Cantor Fitzgerald Overweight $12
Jun-17-22Initiated BMO Capital Markets Outperform $12
Apr-14-22Initiated BTIG Research Buy $18
Nov-16-23 12:00PM
Nov-15-23 07:00AM
Jun-23-23 07:00AM
May-15-23 07:44AM
May-10-23 10:18AM
02:10PM Loading…
Apr-26-23 02:10PM
Mar-29-23 04:20PM
Mar-25-23 10:12AM
Mar-20-23 04:05PM
Feb-23-23 05:36PM
Feb-22-23 04:05PM
Jan-10-23 09:35AM
Jan-06-23 05:54PM
Jan-05-23 05:57PM
04:05PM Loading…
Dec-11-22 10:00AM
Nov-21-22 08:00AM
Nov-17-22 09:45AM
Nov-09-22 04:05PM
Nov-03-22 09:05AM
Oct-16-22 08:33AM
Oct-11-22 08:00AM
Sep-06-22 08:00AM
Aug-30-22 05:47PM
Aug-11-22 04:05PM
Jun-17-22 02:26PM
Jun-01-22 08:00AM
May-29-22 02:15PM
06:00AM Loading…
May-16-22 06:00AM
May-12-22 04:05PM
May-09-22 08:13AM
May-04-22 08:00AM
May-03-22 08:00AM
May-02-22 04:38PM
Mar-28-22 08:00AM
Mar-23-22 12:28PM
Mar-21-22 08:25AM
Mar-03-22 08:00AM
Mar-02-22 08:00AM
Feb-08-22 10:20AM
Jan-27-22 08:00AM
Jan-26-22 06:30PM
Dec-11-21 09:00AM
Dec-07-21 08:00AM
Nov-17-21 08:00AM
Nov-10-21 04:05PM
Nov-04-21 09:13AM
Oct-21-21 08:00AM
Oct-18-21 11:00AM
Oct-12-21 01:00PM
Oct-05-21 08:00AM
Sep-25-21 10:12AM
Aug-30-21 08:00AM
Aug-12-21 04:05PM
Jun-30-21 05:15PM
Jun-24-21 09:08PM
Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA.